Background {#Sec1}
==========

It is well known that hereditary materials and environmental aspects could influence the risks and take a critical part in the tumorigenesis of numerous cancers \[[@CR1], [@CR2]\], nevertheless, the risk attributable to each cancer is indistinct. Of them, an important one is AMP-activated protein kinase (AMPK). As a heterotrimeric protein complex, AMPK always made up of one α, β and γ subunit, respectively, and the 39 kb-long encodes gene (*PRKAA1)* of α-subunit is located at chromosome 5p12.1 \[[@CR3], [@CR4]\]. Numerous pivotal cell metabolic enzymes are regulated by AMPK, through its function of Ser/Thr phosphorylation \[[@CR5]\].AMPK induce the important inhibition of tumorigenesis through multifaceted ways. Firstly, AMPK activation contributes to the inhibition in fatty acid biosynthesis and cholesterol biosynthesis, as well as to the promotion of fatty acid oxidation, therefore, against to the intracellular lipid accumulation and insulin resistance development in non-adipose tissues \[[@CR6]\]. Secondly, another important tumorigenesis related signaling pathway, the mammalian target of rapamycin complex 1 (mTORC1), can be inhibited by the activation of AMPK \[[@CR7]\]. Thirdly, AMPK activation can result in the G1 phase cell cycle arrest, and further impact the cell proliferation through the p53-p21 axis \[[@CR8]\].

Most of the publications concerned about *PRKAA1* polymorphisms focused on its significantly positive association with gastric cancer (GC) \[[@CR9]--[@CR11]\], as well as on breast cancer \[[@CR12]\], but there are also some negative results \[[@CR13]--[@CR16]\]. These conflicting results might be partially affect by the cancer type, origin of control, or sample size. Herein, we managed the meta-analysis to assess whether *PRKAA1* polymorphisms affect susceptibility of cancer.

Methods {#Sec2}
=======

Identification and selection of eligible studies {#Sec3}
------------------------------------------------

Comprehensive literature search on Web of Science, Google Scholar, PubMed, EMbase, CNKI and Wanfang databases was conducted to draw out all eligible case-control studies, and the latest search date is August 26, 2018. The following are valid keyword search strings: (PRKAA1) AND (polymorphism OR SNP OR variant OR mutation OR allele) AND (cancer OR tumor OR tumour OR carcinoma OR neoplasm OR malignancy). What's more, we also manually retrieved the references of reviews or original research on this issue to identify additional studies. For these republished and overlapping studies, we enrolled the most recently published articles or case-control studies with a maximum number of subjects.

Enrolled criteria and excluded criteria {#Sec4}
---------------------------------------

All the eligible studies were enrolled following the details: 1) assess the correlation between the polymorphisms in *PRKAA1* and cancer susceptibility; 2) case-control studies; 3) demonstrate the frequency of genotypes of all cases and controls, or could obtain it via calculating. However, studies would be excluded if they meet the items: 1) animal studies, meta-analysis, comments, reviews or case reports; 2) no efficient data of the genotype frequency; 3) repetitive publications; 4) the research contents were concerned about other disorders instead of cancers.

Extraction of data {#Sec5}
------------------

Extraction of data were independently completed by two authors (Jialin Meng, Xinyao Fan), and all disagreements were finally obtained a consensus after discussion. The following items from the eligible case-control studies were extracted: SNP code, first author, year of publication, ethnicity, cancer type, genotyping method, source of control and genotype frequency. For the control group of each study, we definition it as population-based or hospital-based from whether it is collected from physical examination or just no-cancer patients, and ethnicity was distinguished as "Caucasian" or "Asian".

Statistical analysis {#Sec6}
--------------------

We performed the meta-analyses in the pool, ORs with corresponding 95% CI was recorded to evaluated the strength of the correlation between *PRKAA1* polymorphisms (rs13361707, rs10074991) and cancer susceptibility, the *P* value was adjusted by Bonferroni corrections, *P*~*Adjust*~ = *P*~*Z*~ \* 5 models \[[@CR17]\]. We pooled the ORs for allelic comparison model (B vs. A), heterozygote comparison model (BA vs. AA), homozygote comparison model (BB vs. AA), dominant genetic model (BB + BA vs. AA) and recessive genetic model (BB vs. BA +AA). We further applied Q-test to assess the between study heterogeneity \[[@CR18]\]. When the *P* value of the Q-test was \> 0.1, we selected the Mantel-Haenszel method (fixed model) to evaluate the pooled OR estimate; On the contrast, the Der Simonian and Laird method (random-effect model) was preferred to evaluated the *P* value \< 0.1 group \[[@CR19], [@CR20]\]. In the subgroup of ethnicity and source of control, stratified analyses were also conducted. The Hardy-Weinberg equilibrium (HWE) for the control group was assessed by a professional web-based program (<https://wpcalc.com/en/equilibrium-hardy-weinberg/>), the *P*-value \> 0.05 suggested a HWE balance for the control group. In order to appraise the stability of the meta-analyses, we managed sensitivity analyses by excluding each case-control study and observe whether it influence the pooled ORs and 95% CI \[[@CR21]\]. What's more, Begg's funnel plot and Egger's test was also conducted to avoid any potential publication bias \[[@CR22], [@CR23]\]. All the analysis results were calculated by STATA 12.0 (version 12.0; Stata Corporation). and *P*\<0.05 was regarded as statistically significant.

In-silico analysis {#Sec7}
------------------

To further explore whether the expression of PRKAA1 affect tumorigenesis, we tried to search some evidence from the public TCGA database and GTEx projects, and a newly developed interactive website, GEPIA (<http://gepia.cancer-pku.cn>/), was applied to draw out it \[[@CR24]\].

Results {#Sec8}
=======

Characteristics of studies {#Sec9}
--------------------------

Figure [1](#Fig1){ref-type="fig"} displays the process of searching, a total of 320 publications was firstly retrieved from PubMed, EMbase, Web of Science, CNKI and Wanfang databases. After reviewed the abstract, 54 publications were selected for a further evaluation, however, 30 of them were expurgated because of that they were duplicated studies, case-only studies, or less of efficient data. Finally, 22 case-control studies from 14 publications were enrolled in our study, 17,068 cases and 20,871 controls for rs13361707 \[[@CR9]--[@CR16], [@CR25]--[@CR30]\], while 2514 cases and 3193 controls for rs10074991 \[[@CR10], [@CR12], [@CR27]\] (Table [1](#Tab1){ref-type="table"}**,** Additional file [1](#MOESM1){ref-type="media"}: Table S1). There are 20 case-control studies from Asian descendants, and 2 from Caucasian. Diagnose of tumor was confirmed histologically or pathologically. As to HWE, only three studies were not conformed to it, while the other 19 case-control studies conformed to it. In addition, the result of appraise the quality of study by Newcastle-Ottawa Scale (NOS) is filled in Additional file [1](#MOESM1){ref-type="media"}: Table S2 \[[@CR31]\], and Additional file [1](#MOESM1){ref-type="media"}: Table S3 shows the result of PRISMA2009 checklist \[[@CR32]\].Fig. 1Flow chart showing the study selection procedureTable 1Characteristics of the enrolled studies on PRKAA1 polymorphisms and cancerSNPFirst authorYearEthnicityGenotyping MethodSource of ControlCancer TypeCsaeControlHWEPAAPABPBBHAAHABHBBrs10074991Campa et al.2011CaucasianHapMapHBBC65444594960764149Yrs10074991Kim et al.2014AsianGoldenGate assayPBGC1362429794244136Yrs10074991Eom et al.2016AsianGoldenGate assayPBGC248421177169429248Yrs13361707Shi et al.2011AsianAGWHSA 6.0 chipsPBGC1605173026071154507Yrs13361707Shi et al.2011AsianAGWHSA 6.0 chipsPBGC3719415615781034464Yrs13361707Shi et al.2011AsianAGWHSA 6.0 chipsPBGC237675480392745376Yrs13361707Shi et al.2011AsianAGWHSA 6.0 chipsPBGC2234472257131616898Yrs13361707Shi et al.2011AsianAGWHSA 6.0 chipsPBGC72412214597131616898Yrs13361707Li et al.2013AsianTaqManPBGC971677167165102Yrs13361707Song et al.2013AsianHRM-PCRPBGC9091654682377846477Yrs13361707Dai et al.2014AsianTaqManPBESCC46010545585071144603Yrs13361707Wu et al.2014AsianMultiplex SNaPshot SNPPBGC541154886209133Yrs13361707Kim et al.2014AsianGoldenGate assayPBGC1372419796242135Yrs13361707Sun et al.2014CaucasianTapManHBGC7945668488Yrs13361707Dong et al.2015AsianiMLDRPBGC376862549141Yrs13361707Dong et al.2015AsianiMLDRPBNSCLC417146549141Yrs13361707Dong et al.2015AsianiMLDRPBESCC335123549141Yrs13361707Qiu et al.2015AsianTaqManPBGC344571209273565356Yrs13361707Zhang et al.2016AsianMALDITOFHBGC232710103416Yrs13361707Eom et al.2016AsianGoldenGate assayPBGC249421176174424248Yrs13361707Yuan et al.2016AsianPCRHBGC315926284925Yrs13361707Cai et al.2017AsianKASPPBGC1722138898246143Y*GC* Gastric cancer, *BC* Breast cancer, *ESCC* Esophageal squamous cell carcinoma, *NSCLC* Non-small cell lung cancer, *HB* Hospital based, *PB* Population based, *HWE* Hardy Weinberg Equilibrium

Main results {#Sec10}
------------

Table [2](#Tab2){ref-type="table"} shows the summarized details and results of the meta-analyses. We identified that the rs13361707 polymorphism is not related to the susceptibility of cancer under all five genetic models in the overall population (B vs. A: OR = 0.900, 95%CI = 0.776--1.042, *P*~*Adjust*~ = 0.795; BB vs. AA: OR = 0.810, 95% CI = 0.601--1.092, *P*~*Adjust*~ = 0.830; BA vs. AA: OR = 0.900, 95% CI = 0.768--1.054, *P*~*Adjust*~ = 0.960; BA+AA vs. AA: OR = 0.569, 95% CI = 0.711--1.061, *P*~*Adjust*~ = 0.840; and BB vs. BA+AA: OR = 0.965, 95% CI = 0.714--1.071, *P*~*Adjust*~ = 0.965), and the stratified analysis also indicated no relationships in the subgroups of cancer type, ethnicity and source of control (Fig. [2](#Fig2){ref-type="fig"}). For rs10074991, we revealed a significant decrease risk in allelic comparison model (B vs. A: OR = 0.774, 95% CI = 0.642--0.931, *P*~*Adjust*~ = 3.376\*10^− 2^), heterozygote comparison model (BA vs. AA: OR = 0.779 95%CI = 0.691--0.877, *P*~*Adjust*~ *=* 1.948\*10^− 4^;), and dominant genetic model (BB + BA vs. AA: OR = 0.697 95%CI = 0.533--0.912, *P*~*Adjust*~ = 4.211\*10^− 2^;) (Fig. [3](#Fig3){ref-type="fig"}), and the subgroup of Asian people in rs10074991 shown a prevent potential for tumorigenesis in all five genetic models (B vs. A: OR = 0.704, 95%CI = 0.632--0.785, *P*~*Adjust*~ = 1.085\*10--9; BB vs. AA: OR = 0.489, 95% CI = 0.489 0.392--0.609, *P*~*Adjust*~ = 9.86\*10--10; BA vs. AA: OR = 0.675, 95% CI = 0.558--0.816, *P*~*Adjust*~ = 2.473\*10--4; BA+AA vs. AA: OR = 0.607, 95% CI = 0.507--0.727, *P*~*Adjust*~ = 2.691\*10--7; and BB vs. BA+AA: OR = 0.638, 95% CI = 0.534--0.762, *P*~*Adjust*~ = 3.876\*10--6).Table 2Results of meta-analysis for polymorphisms in and cancer susceptibilityComparisonSubgroupN*P* ~*H*~*P* ~*Z*~*P* ~*Adjust*~Random (OR, 95%CI)Fixed (OR, 95%CI)rs10074991 B VS. Aoverall30.0066.752\*10^−3^3.376\*10^--2\*^0.774 (0.642--0.931)0.795 (0.735--0.861) B VS. AAsian20.9082.169\*10^−10^1.085\*10^--9\*^0.704 (0.632--0.785)0.704 (0.632--0.785) BB vs. AAoverall30.0022.787\*10^−2^0.1390.610 (0.393--0.946)0.627 (0.528--0.745) BB vs. AAAsian20.9541.972\*10^−10^9.86\*10^--10\*^0.489 (0.392--0.609)0.489 (0.392--0.609) BA vs. AAoverall30.1633.895\*10^−5^1.948\*10^--4\*^0.755 (0.633--0.900)0.779 (0.691--0.877) BA vs. AAAsian20.9034.946\*10^−5^2.473\*10^--4\*^0.675 (0.558--0.816)0.675 (0.558--0.816) BB + BA vs. AAoverall30.0118.421\*10^−3^4.211\*10^--2\*^0.697 (0.533--0.912)0.752 (0.672--0.842) BB + BA vs. AAAsian20.9005.381\*10^−8^2.691\*10^--7\*^0.607 (0.507--0.727)0.607 (0.507--0.727) BB vs. BA+AAoverall30.0293.610\*10^−2^0.1810.737 (0.554--0.980)0.729 (0.628--0.846) BB vs. BA+AAAsian20.9997.752\*10^−7^3.876\*10^--6\*^0.638 (0.534--0.762)0.638 (0.534--0.762)rs13361707 B VS. Aoverall196.416\*10^−72^0.1590.7950.900 (0.776--1.042)0.931 (0.904--0.959) B VS. AAsian181.644\*10^−72^0.1880.9400.904 (0.777--1.051)0.932 (0.905--0.960) B VS. AGC162.061\*10^−72^0.1210.6050.873 (0.736--1.037)0.917 (0.889--0.947) B VS. AESCC20.7490.8841.0001.006 (0.927--1.092)1.006 (0.927--1.092) B VS. APB166.359\*10^−73^0.2991.0000.920 (0.786--1.077)0.933 (0.906--0.961) B VS. AHB30.1670.0610.3050.773 (0.555--1.076)0.793 (0.622--1.010) BB vs. AAoverall196.471\*10^−71^0.1660.8300.810 (0.601--1.092)0.868 (0.819--0.921) BB vs. AAAsian181.516\*10^−71^0.1910.9550.816 (0.602--1.106)0.869 (0.819--0.922) BB vs. AAGC162.211\*10^− 71^0.1270.6350.763 (0.539--1.080)1.013 (0.859--1.196) BB vs. AAESCC20.7650.8751.0000.844 (0.792--0.899)1.013 (0.859--1.196) BB vs. AAPB164.978\*10^−72^0.3001.0000.845 (0.615--1.161)0.872 (0.822--0.925) BB vs. AAHB30.1820.0880.4400.592 (0.286--1.224)0.630 (0.371--1.071) BA vs. AAoverall192.232\*10^−20^0.1920.9600.900 (0.768--1.054)0.946 (0.899--0.996) BA vs. AAAsian188.982\*10^− 21^0.2241.0000.904 (0.768--1.064)0.948 (0.900--0.998) BA vs. AAGC161.397\*10^−21^0.1840.9200.883 (0.734--1.061)0.937 (0.886--0.990) BA vs. AAESCC20.7270.9121.0001.008 (0.871--1.167)1.008 (0.871--1.167) BA vs. AAPB169.406\*10^−21^0.3201.0000.919 (0.778--1.086)0.950 (0.902--1.001) BA vs. AAHB30.1210.1550.7750.730 (0.417--1.277)0.768 (0.534--1.105) BB + BA vs. AAoverall191.835\*10^−44^0.1680.8400.869 (0.711--1.061)0.916 (0.873--0.962) BB + BA vs. AAAsian185.451\*10^−45^0.1950.9750.873 (0.71--1.072)0.918 (0.874--0.963) BB + BA vs. AAGC161.594\*10^−45^0.1450.7250.841 (0.666--1.062)0.901 (0.856--0.949) BB + BA vs. AAESCC20.7070.8921.0001.010 (0.879--1.159)1.010 (0.879--1.159) BB + BA vs. AAPB165.135\*10^−45^0.3091.0000.895 (0.723--1.108)0.920 (0.876--0.966) BB + BA vs. AAHB30.0850.2081.0000.692 (0.389--1.228)0.737 (0.522--1.041) BB vs. BA+AAoverall192.761\*10^−46^0.1930.9650.874 (0.714--1.071)0.902 (0.860--0.946) BB vs. BA+AAAsian187.547\*10^−47^0.2171.0000.878 (0.715--1.079)0.902 (0.860--0.947) BB vs. BA+AAGC161.034\*10^−46^0.1350.6750.836 (0.660--1.058)0.882 (0.838--0.929) BB vs. BA+AAESCC20.8920.9171.0001.007 (0.883--1.148)1.007 (0.883--1.148) BB vs. BA+AAPB167.502\*10^−48^0.2931.0000.891 (0.719--1.105)0.904 (0.861--0.948) BB vs. BA+AAHB30.6810.2191.0000.747 (0.470--1.188)0.746 (0.470--1.184)*P*~*H*~ *P* value of Q test for heterogeneity test, *P*~*Z*~ means statistically significant, *P*~*Adjust*~ Multiple testing *P* value according to Bonferroni Correction, *H-B* Hospital based, *P-B* Population based, *HWE* Hardy Weinberg Equilibrium; Note: Heterogeneity was considered to be significant when the *P*-value was less than 0.1. If there was no significant heterogeneity, a fixed effect model (Der-Simonian Laird) was used to evaluate the point estimates and 95% CI; otherwise, a random effects model (Der-Simonian Laird) was used. And the *Pz* was calculated based on the actual model adopted. \"\*\" indicated that *P*~*Adjust*~ value less than 0.05, and is considered as statistically significant  Fig. 2Meta-analysis of the association between *PRKAA1* rs10074991 polymorphism and cancer riskFig. 3Meta-analysis of the association between *PRKAA1* rs13361707 polymorphism and cancer risk

Sensitivity and publication bias analysis {#Sec11}
-----------------------------------------

Sensitivity analysis by delete each signal study were performed to assess whether it influence the overall ORs results. The sensitivity analysis results conducted by all five genetic models were displayed in Fig. [4](#Fig4){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Table S4, no signal study significantly influence the overall ORs results. On the besides, potential publication bias of enrolled case-control studies was appraised by Begg's funnel plot and Egger's test, no publication bias was revealed in both rs13361707 and rs10074991 (Additional file [1](#MOESM1){ref-type="media"}: Figures S1 and S2, Table S5).Fig. 4Sensitivity analysis of Overall OR Co-efficient for *PRKAA1* rs13361707 polymorphism (C vs. T). Results were calculated by omitting each study in turn. The two ends of the dotted lines represent the 95%CI

To further explore whether the expression of PRKAA1 affect tumorigenesis, we tried to search some evidence from the public TCGA database and GTEx projects, and a newly developed interactive website, GEPIA (<http://gepia.cancer-pku.cn/>), was applied to draw out it.

In-silico analysis {#Sec12}
------------------

Evidence from TCGA database and GTEx projects indicated that the expression level of *PRKAA1* in gastric cancer tissue is higher, when compared to normal stomach tissue (TPM = 54.3 vs. 29.2, *P* \< 0.01,), as well as in breast cancer (TPM = 23.1 vs. 29.8, *P* \< 0.01) and esophageal squamous cell carcinoma (TPM = 49.6 vs. 14.9, *P* \< 0.01) (Fig. [5a](#Fig5){ref-type="fig"}). In addition, we analyzed whether the expression of *PRKAA1* affects the overall survival (OS) and disease free survival (RFS) of these four cancers. The Kaplan-Meier estimate showed that there is no significant difference of OS and RFS between the low and high *PRKAA1* TPM groups in gastric cancer (OS: Log-rank *P =* 0.48, RFS: Log-rank *P =* 0.38), breast cancer (OS: Log-rank *P =* 0.34, RFS: Log-rank *P =* 0.98), esophageal carcinoma (OS: Log-rank *P =* 0.096, RFS: Log-rank *P =* 0.7), and lung adenocarcinoma (OS: Log-rank *P =* 0.41, RFS: Log-rank *P =* 0.20).Fig. 5In-silico analysis of *PRKAA1* expression (**a**) The comparison of *PRKAA1* expression between tumor site and matched normal tissue from TCGA database. **b** The correlation between *PRKAA1* expression and overall survival time, disease free survival time in stomach adenocarcinoma (STAD). **c** The correlation between *PRKAA1* expression and overall survival time, disease free survival time in breast cancer (BRCA). **d** The correlation between *PRKAA1* expression and overall survival time, disease free survival time in esophageal carcinoma (ESCA). **e** The correlation between *PRKAA1* expression and overall survival time, disease free survival time in lung adenocarcinoma (LUAD)

Discussion {#Sec13}
==========

AMPK is a highly conserved heterotrimeric Ser/Thr kinase, it could phosphorylates many pivotal downstream targets through the increase ratio of AMP/ATP in environment, affect metabolic pathways of cell growth, cell cycle and autophagy \[[@CR33], [@CR34]\]. In normal cells, the ratio of AMP/ATP is in balance condition, when it is disrupted, many diseases will be followed, as well as malignant disease \[[@CR35]--[@CR37]\]. The underlying genetic mechanisms are still not clearly that how *PRKAA1* gene affect the occurrence and development of cancer, one of them may be the activated AMPK and phosphorylated p53 induced cell cycle G1/S arrest, as well as influenced the cell cycle checkpoint \[[@CR8]\]. On the other way, some publications reported that activated AMPK take pate in the activation of anti-inflammatory agents \[[@CR38]\], as well as inhibition the inflammatory function of macrophage \[[@CR39]\].The lack of anti-inflammatory function will occur with the allele mutation of *PRKAA1* allele, and the patients would suffer from several epithelium disease \[[@CR40]\]. What's more, another potential source of tumorigenesis is the bone marrow-derived cells, because they were reported could be recruited after epithelial damage \[[@CR41]\]. Currently, several studies have demonstrated that *PRKAA1* polymorphisms conduce to the development of gastric cancer, Sun et al. \[[@CR42]\] revealed that LINC00152/miR-139-5p could promote the cell glycolysis of gastric cancer cells through regulating *PRKAA1* expression, Li et al. \[[@CR43]\] indicated that Calcium Binding Protein 39-Like (CAB39L) may be a novel potential regulator for gastric cancer metabolism, which function on activation of PRKAA1/2.

There are several studies concerned about the polymorphisms of *PRKAA1*, and the variant sites include rs154268, rs3805486, rs461404, rs6882903, rs13361707 and rs10074991. After our comprehensive search and analyses, only rs13361707 and rs10074991 have 3 or more studies, so the other studies are excluded. Among these publications, the result is not consistent. Li et al. \[[@CR9]\] and Eom et al. \[[@CR10]\] suggested that rs13361707 polymorphism is remarkable related to an upgraded risk to gastric cancer in Asian and Caucasian, respectively. However, Sun et al. \[[@CR13]\] and Yuan et al. \[[@CR15]\] indicated the controversial result, in their study, rs13361707 of *PRKAA1* doesn't affect the process of gastric cancer. On the meanwhile, the first three study of Shi et al. indicated that T allele of rs13361707 shows a significantly increasing risk of GC, however, Li et al., Kim et al. and Cai et al. revealed that the mutant allele of rs13361707 (C allele) caused enhanced risk of GC. In another case-control study conducted by Dai et al. \[[@CR16]\], they revealed that the polymorphism of rs13361707 also doesn't work in esophageal squamous cell carcinoma. In current study, we identified that the rs13361707 polymorphism would not affect the susceptibility of cancer in the overall population. For rs10074991, Eom et al. \[[@CR10]\] and Kim et al. \[[@CR27]\] only reported partial increase cancer risks in several genetic models, while Campa et al. \[[@CR12]\] revealed that rs10074991 is not associated with the tumorigenesis of breast cancer.

We revealed a significant decrease risk in allelic comparison model, heterozygote comparison model and dominant genetic model. Rs10074991 and rs13361707 polymorphisms both located at the intron of *PRKAA1*, within the perfect LD (R^2^ = 1.00). In a book named "Personalized Management of Gastric Cancer", Zhu et al. \[[@CR44]\] demonstrated that the rs13361707 LD block mainly spans PTGER4, TTC33, and *PRKAA1* gene, and a remarkable relationships between rs13361707 and these three genes were shown in the results from GTEx, so the polymorphism of rs13361707 might influence the expression of *PRKAA1*. In the current study, we enrolled all eligible case-control studies, from different race to different cancer types, aim to draw a systemic result for readers, and stratified analysis was also performed to avoid the bias. For example, the allele frequency of rs10074991, rs13361707 for all the enrolled Asian population based studies are ranged from 40 to 60%, while the Caucasian population based studies are ranged about 80% (Additional file [1](#MOESM1){ref-type="media"}: Table S1), it might cause by the ethnic difference. We exceed the Caucasian based study, and the overall result was not influenced (Table [2](#Tab2){ref-type="table"}), but the future studies show focused on this difference between Asian and Caucasian. In the analysis of rs13361707, we also conducted the stratified analysis by the source of control, in order to reduce the heterogeneity of Q-test, however, the result in HB based subgroup or PB based subgroup is consistent with the result of overall pooled result. To confirm the result, large well-designed epidemiological studies based on population controls should be managed in the future.

There are several advantages of this meta-analysis. Initially, we enrolled all eligible studies focused on the relationships between PRKAA1 polymorphisms and overall cancer risks to conducted a comprehensive meta-analysis. Furthermore, NOS method was used to assess the quality of each accepted case-control study, and exceed the low quality studies to make sure the reliability of pooled result. Additionally, eligible studies were stratified and calculated in different subgroups to reduce the impact of heterogeneity, including subgroup of ethnicity, cancer type and source of control. Another point, the *P* value of Z was adjusted by Bonferroni corrections (*P*~*Adjust*~), aim to avoiding the false positive results. Finally, the stability of results was assessed by sensitivity analysis, and potential publication bias was eliminating from the results of Egger's test and Begg's funnel plot.

However, there are also several disadvantages. To begin with, the untrustworthy result may be obtained, because of lack of subjects in several genetic polymorphisms. What's more, potential enrolled bias may be existed, due to that only publications written in English or Chinese were assessed. Then, most of the enrolled studies are concerned about GC, only 2 about ESCC, 1 about breast cancer, and 1 about lung cancer, therefore, the meta-analysis result might not be able to illustrated the impact of rs10074991 and rs13361707 in overall cancer risk. Last but not least, the striking level of heterogeneity between the enrolled publications might influence the result, although we conducted the meta-analysis with Der Simonian and Laird method.

Conclusion {#Sec14}
==========

Our data have successfully elaborated that *PRKAA1* rs13361707 polymorphism is not participant with increased risk of cancer, while the A allele of *PRKAA1* rs10074991 revealed a significant decrease risk, especially in Asian population. In the future., larger sample size studies based on numerous cancer types should be conducted to confirm the exploration of this issue.

Additional file
===============

 {#Sec15}

Additional file 1:**Table S1.** Total sample sizes and allelic percentages of enrolled studies. **Table S2.** Methodological quality of the included studies according to the Newcastle-Ottawa Scale. **Table S3.** PRISMA 2009 Checklist. **Table S4.** Details of the sensitivity analyses for the polymorphisms in *PRKAA1* and cancer risk. **Table S5.** *P* values of the Egger's test for the polymorphisms in *PRKAA1*. **Figure S1.** Begg's funnel plot for publication bias for *PRKAA1 rs13361707* polymorphism (B vs. A). For Begg's funnel plot, the x-axis is log (OR), and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. **Figure S2.** Begg's funnel plot for publication bias for *PRKAA1 rs10074991* polymorphism (B vs. A). For Begg's funnel plot, the x-axis is log (OR), and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. **Figure S3.** Sensitivity analysis of Asian based group OR Co-efficient for PRKAA1 rs13361707 polymorphism (C vs. T). Results were calculated by omitting each study in turn. The two ends of the dotted lines represent the 95% CI. (PDF 1760 kb)
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